Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer
BACKGROUND: PI3K/mTOR inhibition leads to apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma (HNSCC) cells. We tested the efficacy of the PI3K/mTOR inhibitor bimiralisib in patients with NOTCH1-mutant HNSCC. METHODS: Patients with recurrent/metastatic NOTCH1-mutant HNSCC who had progre...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732253/ https://www.ncbi.nlm.nih.gov/pubmed/36124629 http://dx.doi.org/10.1093/oncolo/oyac185 |
_version_ | 1784846086494486528 |
---|---|
author | Johnson, Faye M Janku, Filip Gouda, Mohamed A Tran, Hai T Kawedia, Jitesh D Schmitz, Debora Streefkerk, Hendrik Lee, J Jack Andersen, Clark R Deng, Defeng Rawal, Seema Shah, Pooja A El-Naggar, Adel K Johnson, Jason M Frederick, Mitchell J |
author_facet | Johnson, Faye M Janku, Filip Gouda, Mohamed A Tran, Hai T Kawedia, Jitesh D Schmitz, Debora Streefkerk, Hendrik Lee, J Jack Andersen, Clark R Deng, Defeng Rawal, Seema Shah, Pooja A El-Naggar, Adel K Johnson, Jason M Frederick, Mitchell J |
author_sort | Johnson, Faye M |
collection | PubMed |
description | BACKGROUND: PI3K/mTOR inhibition leads to apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma (HNSCC) cells. We tested the efficacy of the PI3K/mTOR inhibitor bimiralisib in patients with NOTCH1-mutant HNSCC. METHODS: Patients with recurrent/metastatic NOTCH1-mutant HNSCC who had progressed during chemotherapy and immunotherapy received bimiralisib until unacceptable toxicity or progression. To assess whether NOTCH1 mutations can be detected in blood, we measured circulating tumor DNA (ctDNA). To assess activated NOTCH1 protein levels, we quantitated cleaved NOTCH1 (cl-NOTCH) by immunohistochemistry. RESULTS: Eight patients were treated, and 6 were evaluable for response. The objective response rate was 17%. For all 8 patients, median progression-free and overall survival was 5 and 7 months, respectively. Bimiralisib was well tolerated, with expected hyperglycemia. Pharmacokinetic values were consistent with published studies. NOTCH1 mutations were detected in 83.3% of ctDNA. Staining for tumor cl-NOTCH1 was negative. The trial closed early due to sponsor insolvency. CONCLUSION: Although the trial was small, outcomes with bimiralisib were better than the historical standard of care; Results will need to be confirmed in a larger trial. The lack of cl-NOTCH1 was consistent with loss-of-function mutations and validated our mutation function algorithm. The ability to detect NOTCH1 mutations in blood will help future studies. (ClinicalTrials.gov Identifier: NCT03740100). |
format | Online Article Text |
id | pubmed-9732253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97322532022-12-13 Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer Johnson, Faye M Janku, Filip Gouda, Mohamed A Tran, Hai T Kawedia, Jitesh D Schmitz, Debora Streefkerk, Hendrik Lee, J Jack Andersen, Clark R Deng, Defeng Rawal, Seema Shah, Pooja A El-Naggar, Adel K Johnson, Jason M Frederick, Mitchell J Oncologist Clinical Trial Results BACKGROUND: PI3K/mTOR inhibition leads to apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma (HNSCC) cells. We tested the efficacy of the PI3K/mTOR inhibitor bimiralisib in patients with NOTCH1-mutant HNSCC. METHODS: Patients with recurrent/metastatic NOTCH1-mutant HNSCC who had progressed during chemotherapy and immunotherapy received bimiralisib until unacceptable toxicity or progression. To assess whether NOTCH1 mutations can be detected in blood, we measured circulating tumor DNA (ctDNA). To assess activated NOTCH1 protein levels, we quantitated cleaved NOTCH1 (cl-NOTCH) by immunohistochemistry. RESULTS: Eight patients were treated, and 6 were evaluable for response. The objective response rate was 17%. For all 8 patients, median progression-free and overall survival was 5 and 7 months, respectively. Bimiralisib was well tolerated, with expected hyperglycemia. Pharmacokinetic values were consistent with published studies. NOTCH1 mutations were detected in 83.3% of ctDNA. Staining for tumor cl-NOTCH1 was negative. The trial closed early due to sponsor insolvency. CONCLUSION: Although the trial was small, outcomes with bimiralisib were better than the historical standard of care; Results will need to be confirmed in a larger trial. The lack of cl-NOTCH1 was consistent with loss-of-function mutations and validated our mutation function algorithm. The ability to detect NOTCH1 mutations in blood will help future studies. (ClinicalTrials.gov Identifier: NCT03740100). Oxford University Press 2022-09-16 /pmc/articles/PMC9732253/ /pubmed/36124629 http://dx.doi.org/10.1093/oncolo/oyac185 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Trial Results Johnson, Faye M Janku, Filip Gouda, Mohamed A Tran, Hai T Kawedia, Jitesh D Schmitz, Debora Streefkerk, Hendrik Lee, J Jack Andersen, Clark R Deng, Defeng Rawal, Seema Shah, Pooja A El-Naggar, Adel K Johnson, Jason M Frederick, Mitchell J Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer |
title | Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer |
title_full | Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer |
title_fullStr | Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer |
title_full_unstemmed | Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer |
title_short | Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer |
title_sort | inhibition of the phosphatidylinositol-3 kinase pathway using bimiralisib in loss-of-function notch1-mutant head and neck cancer |
topic | Clinical Trial Results |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732253/ https://www.ncbi.nlm.nih.gov/pubmed/36124629 http://dx.doi.org/10.1093/oncolo/oyac185 |
work_keys_str_mv | AT johnsonfayem inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT jankufilip inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT goudamohameda inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT tranhait inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT kawediajiteshd inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT schmitzdebora inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT streefkerkhendrik inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT leejjack inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT andersenclarkr inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT dengdefeng inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT rawalseema inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT shahpoojaa inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT elnaggaradelk inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT johnsonjasonm inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer AT frederickmitchellj inhibitionofthephosphatidylinositol3kinasepathwayusingbimiralisibinlossoffunctionnotch1mutantheadandneckcancer |